Phase I multiple-dose safety, pharmacokinetic, and pharmacodynamic clinical study of nitric oxide releasing aspirin (NCX-4016)

Trial Profile

Phase I multiple-dose safety, pharmacokinetic, and pharmacodynamic clinical study of nitric oxide releasing aspirin (NCX-4016)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2007

At a glance

  • Drugs NCX 4016 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jun 2007 Status changed from recruiting to discontinued.
    • 05 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top